

A Real-World Study Evaluating Drug Tolerability and Health Care Resource Use with Acalabrutinib Versus Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Daniel Ermann¹, George Dranitsaris^{2,3}, Sibel Blau², Aaron Peevyhouse², Heather Neuhalfen², Vikram Shetty⁴, Dipen Patel⁴, Samantha L Thompson⁵, Anna Teschemaker⁴, and Mayur Narkhede⁶

¹University of Utah, Salt Lake City, UT, USA, ²ONCare Alliance, Tacoma, WA, USA, ³Syracuse University, Syracuse, NY, USA, ⁴AstraZeneca, Gaithersburg, MD, USA, ⁵AstraZeneca, Cambridge, UK, ⁶The University of Alabama at Birmingham, Birmingham, AL, USA

EE35

Supplementary Materials

Supplementary Table 1. Demographic and clinical characteristics of patients at the start of BTKi monotherapy

Parameter ^a	Acalabrutinib n = 90	Ibrutinib n = 180
Median age, years (IQR)	74.5 (54–89)	70.0 (47–88)
Female sex, n (%)	30 (33.3)	58 (32.2)
Race, n (%)		
White	83 (92.2)	155 (86.1)
Black	3 (3.3)	17 (9.4)
Other	3 (3.3)	5 (2.8)
Not documented	1 (1.1)	3 (1.7)
ECOG PS, n (%)		
0	38 (42.2)	65 (36.1)
1	36 (40.0)	59 (32.8)
≥ 2	7 (7.8)	15 (8.3)
Not documented	9 (10.0)	41 (22.8)
SBP at start of therapy (IQR)	124 (102–161)	130 (99–184)
DBP at start of therapy (IQR)	72 (50–89)	74 (55–99)
Median Charlson comorbidity index (IQR)^b	3 (2–8)	3 (2–8)
Clinical history 12 months before therapy, n (%)		
Atrial fibrillation	13 (14.4)	19 (10.6)
Atrial flutter	1 (1.1)	0 (0.0)
Cardiac arrhythmia	1 (1.1)	3 (1.7)
Cerebrovascular accident	1 (1.1)	0 (0.0)
Congestive heart failure	4 (4.4)	6 (3.3)
Hypertension	51 (56.7)	105 (58.3)
Valvular heart disease	5 (5.6)	3 (1.7)
Myocardial infarction	1 (1.1)	1 (0.6)
Clinically significant bleeding events	2 (2.2)	1 (0.6)
Venous thromboembolic event	3 (3.3)	1 (0.6)
Left ventricular dysfunction	1 (1.1)	2 (1.1)
Ventricular arrhythmia	0 (0.0)	2 (1.1)
Transient ischemic attack	1 (1.1)	0 (0.0)

^aPercentages may not total 100 owing to rounding.

^bThe weighted comorbidity classes were: low = 0 points; median = 1–2; high = 3–4; and very high = ≥ 5.

BTKi, Bruton tyrosine kinase inhibitor; DBP, diastolic blood pressure; ECOG PS, Eastern Oncology Cooperative Group performance status; IQR, interquartile range; SBP, systolic blood pressure.

Supplementary Table 2. Supportive care drugs received during BTKi therapy

Parameter, n (%)	Acalabrutinib n = 90	Ibrutinib n = 180
ACE inhibitors	18 (20.0)	45 (25.0)
Calcium-channel blockers	21 (23.3)	43 (23.9)
α₂-receptor agonists	0 (0.0)	4 (2.2)
β-blockers	27 (30.0)	56 (31.1)
Angiotensin II receptor blockers	10 (11.1)	34 (18.9)
Diuretics	19 (21.1)	55 (30.6)
α-blockers	6 (6.7)	5 (2.8)
Vasodilators	1 (1.1)	3 (1.7)
Clopidogrel	4 (4.4)	6 (3.3)
Apixaban	4 (4.4)	11 (6.1)
Rivaroxaban	6 (6.7)	8 (4.4)
Dabigatran	1 (1.1)	2 (1.1)
Warfarin	3 (3.3)	8 (4.4)

ACE, angiotensin-converting enzyme; BTKi, Bruton tyrosine kinase inhibitor.